Literature DB >> 3486617

Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities.

V Falanga, T A Medsger, M Reichlin, G P Rodnan.   

Abstract

The clinical features and natural history of linear scleroderma in 53 patients and the laboratory tests helpful in the management of this disease are described. No patient had Raynaud's phenomenon or signs of systemic connective tissue disease in a mean follow-up of 10 years. Blood eosinophilia (greater than 300 cells/mm3) was present in half the patients, usually those with clinically active disease rather than inactive disease (p less than 0.02). An elevated serum IgG level correlated with the presence of joint contractures (p less than 0.02). Antinuclear antibodies, commoner in patients with extensive and prolonged disease, were present in 31% and 46% of patients whose sera were tested on mouse kidney and HEp-2 cells, respectively. Antibodies to single-stranded DNA, present in 50% of patients, were associated with extensive disease, joint contractures (p less than 0.001), and active disease of greater than 2 years' duration (p less than 0.001). Discordance in immune reactivity indicates that at least three serum autoantibodies exist in these patients: antibodies to single-stranded DNA and antinuclear antibodies with homogeneous and nucleolar immunofluorescence patterns.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486617     DOI: 10.7326/0003-4819-104-6-849

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

1.  Auto-immune disorders in localized scleroderma.

Authors:  R Rondinone; M Germino; E Sartori; C Veller Fornasa; A Ruffatti; C Betterle; A Peserico
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Elevated soluble CD23 levels in the sera from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

Review 3.  Systemic manifestations in localized scleroderma.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

4.  Thermography for evaluation of localized scleroderma treated with methotrexate and corticosteroid.

Authors:  Yasuyo Kashiwagi; Hisashi Kawashima; Kazushi Agata; Mai Akaba; Akane Hirose; Soken Go; Shigeo Nishimata; Yoshihito Mitsuhashi; Ryoji Tsuboi
Journal:  Indian J Pediatr       Date:  2013-07-12       Impact factor: 1.967

5.  Shiny white patches of the arms and forehead.

Authors:  Jason Emer; Dean David George; Sebastian Bernardo; Harleen Sidhu
Journal:  J Clin Aesthet Dermatol       Date:  2013-08

6.  Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study.

Authors:  Kathryn S Torok; Thaschawee Arkachaisri
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

Review 7.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

8.  Soluble CD4 and CD8 in serum from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

9.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

Review 10.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.